Maa: Kanada
Kieli: englanti
Lähde: Health Canada
CEFACLOR
MM THERAPEUTICS INC
J01DC04
CEFACLOR
250MG
CAPSULE
CEFACLOR 250MG
ORAL
250
Prescription
SECOND GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0113428003; AHFS:
CANCELLED POST MARKET
2009-12-18
PRODUCT MONOGRAPH PR CEFACLOR (Cefaclor Capsules and Oral Suspensions) 250 mg, 500 mg, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL ANTIBIOTIC MM THERAPEUTICS INC. Date of Preparation: 6111 Royalmount Avenue, Suite 100 OCTOBER 9, 2009 Montreal, Quebec H4P 2T4 Control # :133194 2 PRODUCT MONOGRAPH PR CEFACLOR (Cefaclor Capsules and Oral Suspensions) 250 mg, 500 mg, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL THERAPEUTIC CLASSIFICATION Antibiotic ACTION Like other $ -lactam antibiotics, cefaclor owes its antibacterial activity to its ability to bind to and inhibit the action of certain bacterial cell wall synthetic enzymes, the penicillin-binding proteins. CLINICAL PHARMACOLOGY CEFACLOR (cefaclor capsules and oral suspensions): is well absorbed after oral administration to fed and fasted subjects. Following doses of 250 mg, 500 mg and 1 g to fasted subjects, average peak serum levels of approximately 7, 13 and 23 mg/L respectively were obtained within 0.5 to 1.0 hour. Total absorption is the same whether the drug is given before or after meals. However, when it is taken after food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasted subjects and is delayed by 0.8 to 1 hour. Approximately 25% of cefaclor is bound to human plasma. Within 8 hours 60% to 85% of the drug is excreted unchanged in the urine, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations 3 following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mg/L respectively. The serum half-life in normal subjects is 0.6 to 0.9 hours. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%. Probenecid administered with a 500 mg dose of CEFA Lue koko asiakirja